Dr. Diana Hausman, M.D.
Diana F. Hausman, M.D. has served on our Board of Directors since January 2022. Dr. Hausman is the Chief Medical Officer (CMO) of Zentalis Pharmaceuticals. From March 2022 until October 2023, she served as the CMO of Link Immunotherapeutics, and from June 2021 to March 2022, as CMO of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines Corporation. Prior to Lengo, Dr. Hausman served as CMO for Zymeworks Inc. from June 2016 to May 2021 and as CMO for Oncothyreon Inc from 2009 to 2016. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle, WA. She received her MD degree from the University of Pennsylvania and an A.B in biology from Princeton University. We believe Dr. Hausman’s extensive experience in the life sciences industry and her medical background qualifies her to serve on our Board of Directors.